Urinary Tract Infection Testing Market Size & Growth Forecast 2027–2036, By Segments (Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Urinary Tract Infection Testing Market size was estimated at USD 726.1 million in 2026 and is projected to grow at a 5.23% CAGR from 2027 to 2036, attaining USD 1.21 billion by 2036. The industry revenue for 2027 is calculated at USD 758.05 million.
Get more details on this report
Request Free Sample ReportUrinary Tract Infection Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to strong diagnostic laboratory access, established clinical testing pathways, and high healthcare utilization for symptomatic urinary infections.
- Asia Pacific growth at 5.24% CAGR is driven by expanding healthcare access, increasing patient entry into formal care systems, and improved availability of diagnostic testing services.
Segment Momentum
- Cystitis accounted for 43.88% of the market in 2026, supported by high testing volumes from routine lower urinary tract infection diagnosis and consistent demand across everyday clinical workflows.
- Urogynecologists are the fastest-growing end-use segment as more patients with recurrent or complex urinary conditions require specialized diagnostic evaluations and targeted testing approaches.
Market Expansion Drivers
- Rising prevalence of recurrent urinary tract infections increasing diagnostic testing volumes among women populations.
- Expanding adoption of point-of-care and at-home UTI testing kits improving accessibility and convenience.
- Growing investment in smartphone-enabled rapid diagnostic technologies enhancing decentralized infection screening capabilities.
Leading Market Participants
- Major players in the urinary tract infection testing market include bioMérieux SA (France), Roche Holding AG (Switzerland), QIAGEN N.V. (Germany), Danaher Corporation (United States), Thermo Fisher Scientific Inc. (United States), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (United States), Abbott Laboratories (United States), Randox Laboratories Ltd. (United Kingdom), T2 Biosystems, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 726.1 million
- 2027 Estimated Market Size: USD 758.05 million.
- Projected Market Size: USD 1.21 billion by 2036
- Growth Forecast: 5.23% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Cystitis (Type) | Reference Laboratories (End Use)
- Emerging Opportunity Segment: Pyelonephritis (Type) | Urogynecologists (End Use)
Market Growth Drivers and Industry Trends
Rising prevalence of recurrent urinary tract infections increasing diagnostic testing volumes among women populations
Recurrent urinary tract infections among women are increasing the need for repeated and timely diagnostic assessment, creating sustained demand within the urinary tract infection testing market. Frequent episodes can require confirmation of infection, identification of the causative organism, and evaluation of treatment response to help guide appropriate clinical management. Women experiencing recurring symptoms may undergo testing more frequently than patients with isolated infections, increasing utilization across physician offices, diagnostic laboratories, and other healthcare settings. The need to distinguish bacterial infection from conditions with similar symptoms also reinforces the role of reliable testing in avoiding inappropriate treatment.
Expanding adoption of point-of-care and at-home UTI testing kits improving accessibility and convenience
The urinary tract infection testing market is gaining momentum from the wider use of point-of-care and at-home testing kits that allow individuals to assess suspected infections with greater convenience. These solutions can reduce dependence on laboratory visits for initial screening and provide rapid indications that may encourage patients to seek appropriate medical evaluation. Point-of-care testing is particularly useful in settings where immediate assessment can support faster clinical decisions, while home-based formats improve accessibility for individuals facing time, mobility, or geographic barriers. Easier access to preliminary testing can also increase awareness of symptoms and encourage earlier engagement with healthcare services.
Growing investment in smartphone-enabled rapid diagnostic technologies enhancing decentralized infection screening capabilities
Investment in smartphone-enabled diagnostic technologies is creating new opportunities for decentralized infection screening by combining rapid testing with digital connectivity. Such technologies can support the urinary tract infection testing market growth by enabling test results to be captured, interpreted, and communicated through widely available mobile devices. Smartphone integration may facilitate remote monitoring and digital documentation while reducing dependence on conventional laboratory infrastructure for certain screening applications. Development of compact diagnostic platforms that connect test outputs with mobile applications is also supporting more convenient testing workflows in community, home, and other decentralized healthcare environments.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of recurrent urinary tract infections increasing diagnostic testing volumes among women populations | 1.80% | Moderate | North America, Europe | High | Near Term |
| Expanding adoption of point-of-care and at-home UTI testing kits improving accessibility and convenience | 1.50% | Moderate | North America, Asia Pacific | High | Mid Term |
| Growing investment in smartphone-enabled rapid diagnostic technologies enhancing decentralized infection screening capabilities | 1.20% | Moderate | Asia Pacific, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the urinary tract infection testing market in 2026, supported by advanced diagnostic infrastructure, broad access to laboratory services, and established clinical practices for identifying urinary infections. Strong emphasis on rapid and accurate diagnosis is encouraging the use of efficient testing technologies across hospitals, clinics, and diagnostic centers. Growing demand for timely treatment, combined with healthcare providers’ focus on reducing complications associated with untreated or recurrent infections, continues to support the region’s leading position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing region, driven by expanding healthcare infrastructure, increasing diagnostic awareness, and improved access to testing services. Rising healthcare utilization and broader adoption of point-of-care and laboratory-based diagnostic technologies are helping strengthen the regional testing ecosystem. Greater attention to infection management, increasing availability of healthcare facilities, and ongoing improvements in diagnostic capacity are expected to accelerate demand for urinary tract infection testing across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Efficiency FocusGermany emphasizes standardized laboratory workflows and reliable urine diagnostics to improve testing consistency and reduce unnecessary antibiotic use. Clinical laboratories are expanding automated testing solutions that strengthen diagnostic quality while supporting efficient healthcare delivery.
France 🇫🇷
Antimicrobial Stewardship SupportFrance is strengthening urinary tract infection testing practices that align with antimicrobial stewardship initiatives and evidence-based prescribing. Clinical laboratories are adopting more accurate diagnostic technologies to reduce unnecessary antibiotic use and improve patient management.
Italy 🇮🇹
Hospital Testing ModernizationItaly is modernizing urinary tract infection testing through investments in laboratory automation and standardized diagnostic protocols. Healthcare providers are improving access to reliable testing methods that support faster diagnosis and more targeted treatment decisions.
Japan 🇯🇵
Aging Care DiagnosticsJapan is expanding urinary tract infection testing to address the clinical needs of its aging population and long-term care facilities. Greater use of accurate diagnostic methods helps clinicians differentiate infections quickly while supporting appropriate treatment selection.
South Korea 🇰🇷
Digital Laboratory AdoptionSouth Korea is integrating advanced urinary tract infection testing with digitally connected laboratory systems to improve turnaround times and diagnostic precision. Healthcare providers are adopting automated platforms that enhance workflow efficiency in both hospital and reference laboratory settings.
United States 🇺🇸
Rapid Diagnostic IntegrationThe U.S. is prioritizing rapid urinary tract infection testing that supports antimicrobial stewardship and improves diagnostic accuracy across hospitals, urgent care centers, and outpatient clinics. Demand is encouraging broader adoption of automated and molecular testing platforms for faster clinical decision-making.
Segment Leadership and Growth Trends
Urinary Tract Infection Testing Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Cystitis (Largest Segment) vs Pyelonephritis (Fastest-Growing Segment)
Cystitis represented the largest share of the type segment of the urinary tract infection testing market, accounting for 43.88% in 2026. Its prominent position reflects the high diagnostic demand associated with lower urinary tract infections and the need for timely identification to support appropriate clinical management. Frequent occurrence among patients and the importance of distinguishing urinary infections from other conditions contribute to continued testing requirements. Growing awareness of urinary tract health and increasing emphasis on accurate diagnosis are further supporting demand for cystitis-related testing.
Pyelonephritis is anticipated to be the fastest-growing type as healthcare providers place greater emphasis on identifying more serious urinary infections that can involve the upper urinary tract. The potential for complications associated with untreated or inadequately managed infections increases the importance of timely and reliable diagnostic assessment. Greater clinical attention to infection severity, coupled with the need to guide appropriate treatment decisions, is supporting increasing demand for testing associated with pyelonephritis.
End Use Segment Analysis: Reference Laboratories (Largest Segment) vs Urogynecologists (Fastest-Growing Segment)
Reference laboratories accounted for the largest share of the end use segment of the urinary tract infection testing market, with a 28.84% share in 2026. Their strong position is supported by the availability of specialized testing infrastructure and analytical expertise capable of handling diagnostic workloads from diverse healthcare settings. Reference laboratories can support consistent testing and provide access to advanced diagnostic capabilities, making them important partners for healthcare providers requiring reliable urinary tract infection analysis. Increasing demand for accurate laboratory confirmation is reinforcing their role across the diagnostic pathway.
Urogynecologists are expected to represent the fastest-growing end-use group as greater clinical attention is directed toward urinary and pelvic health conditions requiring specialized evaluation. These specialists are well positioned to assess recurrent or complex urinary symptoms and integrate diagnostic testing into individualized patient management. Growing recognition of the need for specialized care, combined with increased emphasis on precise identification of urinary tract conditions, is supporting greater utilization of testing among urogynecologists.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Urethritis, Cystitis, Pyelonephritis | Cystitis | Pyelonephritis |
| End Use | General Practitioners (GPs), Urologists, Urogynecologists, Hospital Laboratories, Reference Laboratories, Hospital Emergency Departments, Urgent Care, Others | Reference Laboratories | Urogynecologists |
Competitive Landscape and Market Positioning
Prominent players in the urinary tract infection testing market:
1. bioMérieux SA (France)
2. Roche Holding AG (Switzerland)
3. QIAGEN N.V. (Germany)
4. Danaher Corporation (United States)
5. Thermo Fisher Scientific Inc. (United States)
6. Siemens Healthineers AG (Germany)
7. Becton Dickinson and Company (United States)
8. Abbott Laboratories (United States)
9. Randox Laboratories Ltd. (United Kingdom)
10. T2 Biosystems Inc. (United States)
Increasing demand for faster and more accurate infectious disease diagnosis is shaping developments in the urinary tract infection testing market. Companies are focusing on automated and rapid-testing platforms that minimize turnaround times while improving detection sensitivity. The growing use of point-of-care diagnostics and digital laboratory integration is also contributing to enhanced workflow efficiency and broader accessibility of testing solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| bioMérieux SA (France) | |||||||
| Roche Holding AG (Switzerland) | |||||||
| QIAGEN N.V. (Germany) | |||||||
| Danaher Corporation (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Abbott Laboratories (United States) | |||||||
| Randox Laboratories Ltd. (United Kingdom) | |||||||
| T2 Biosystems Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Mankind Pharma | Sep-24 | Mankind Pharma launched a self-test kit for the rapid detection of urinary tract infections. By enabling patients to identify leukocyte and nitrite markers at home, the product addresses the growing demand for convenient, private, and accessible diagnostic solutions, strengthening the company's competitive position within the consumer-focused diagnostic segment. |
| Thermo Fisher Scientific | Dec-22 | Thermo Fisher Scientific launched TrueMark Infectious Disease Research Panels, a technology suite designed for the rapid and accurate detection of microorganisms associated with urinary, respiratory, and gastrointestinal conditions. This development enhances the company’s molecular diagnostic capabilities, providing high-precision tools for identifying pathogens and associated antimicrobial resistance markers in diverse clinical settings. |
| Sysmex Corporation | Sep-22 | Sysmex Corporation introduced the UF-1500, a fully automated urine particle analyzer designed to optimize urine sediment testing. The platform improves laboratory efficiency and standardization in diagnostic workflows. This product launch represents a strategic effort to enhance high-throughput testing capabilities, providing clinical laboratories with a reliable automated solution for detecting infection markers in urine samples. |
| Vela Diagnostics | May-22 | Vela Diagnostics launched the AMR PCR Test alongside the PathoKey MP UTI ID kit. These diagnostic solutions are specifically engineered to detect UTI-causing pathogens and screen for antimicrobial resistance genes. The integration of pathogen identification and resistance profiling provides clinicians with actionable data to inform antibiotic therapy, addressing a critical need for precision in infectious disease management. |
| BD (Becton, Dickinson and Company) | Dec-21 | BD completed the acquisition of Scanwell Health Inc., a developer of smartphone-aided at-home medical test kits. This acquisition signifies a strategic move to integrate digital health technologies with diagnostic testing, expanding BD's footprint in the decentralized and at-home testing market, which is increasingly relevant for routine monitoring and screening of urinary tract infections. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Urinary Tract Infection Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Diagnostic Method | Urinalysis, Urine Culture, Molecular Testing, Antimicrobial Susceptibility Testing |
| Sample Type | Midstream Urine, Catheterized Urine, Suprapubic Aspirate, First-Morning Urine |
| Care Pathway Stage | Initial Diagnosis, Treatment Selection & Monitoring, Recurrence Assessment |
Urinary Tract Infection Testing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Antimicrobial Stewardship Impact |
|
| Rapid UTI Testing Adoption |
|
| Primary Care Diagnostic Pathway |
|
Need a different cut of the data?
Request Custom ResearchHow big is the urinary tract infection testing market?
How will the urinary tract infection testing industry grow in terms of size and CAGR by 2036?
How are point-of-care and at-home testing solutions changing demand in the urinary tract infection testing market?
Why are smartphone-enabled diagnostic platforms gaining traction in the urinary tract infection testing market?
What makes Cystitis the largest segment in the urinary tract infection testing market?
Why are Urogynecologists becoming the fastest-growing end users in the market?
Why does North America lead the urinary tract infection testing market?
What is driving growth in Asia Pacific for urinary tract infection testing?
Who are the major participants shaping the urinary tract infection testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization